Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human breast cancer samples

ABSTRACT: We measured baseline gene expression profiles for a set of breast tumors. Note: this experiment was modified in June 2008 when the CEL files associated with some hybridizations were changed.

ORGANISM(S): Homo sapiens

SUBMITTER: Riis ML

PROVIDER: S-ECPF-TABM-158 | biostudies-other | 2013

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of human pre-malignant breast cancer samples

Project description: Not available

| S-ECPF-GEOD-7377 | biostudies-other

N-glycan profiling of tissue samples to aid breast cancer subtyping.

Project description: Not available

| S-EPMC10764792 | biostudies-literature

Transcription profiling of human breast cancer samples

Project description:We measured baseline gene expression profiles for a set of breast tumors. Note: this experiment was modified in June 2008 when the CEL files associated with some hybridizations were changed.

2008-06-28 | E-TABM-158 | biostudies-arrayexpress

Transcription profiling by array of 17 human breast cancer samples

Project description: Not available

| S-ECPF-MTAB-1088 | biostudies-other

Transcription profiling of human breast cancer samples - relapse free survival

Project description: Not available

| S-ECPF-GEOD-2034 | biostudies-other

Transcription profiling of human liver cancer samples

Project description: Not available

| S-DIXA-D-1187 | biostudies-other

Transcription profiling of human breast cancer samples to discover and validate breast cancer subtypes

Project description: Not available

| S-ECPF-SMDB-3831 | biostudies-other

Transcription profiling of human breast cancer samples to discover and validate breast cancer subtypes

Project description: Not available

| S-ECPF-SMDB-3830 | biostudies-other

Transcription profiling of human pre-malignant breast cancer samples

Project description:Enlargement of normal terminal duct lobular units (TDLUs) by hyperplastic columnar epithelial cells is one of the most common abnormalities of growth in the adult female human breast. These hyperplastic enlarged lobular units (HELUs) are important clinically as the earliest histologically identifiable potential precursor of breast cancer. The causes of the hyperplasia are unknown but may include estrogen-simulated growth mediated by estrogen receptor alpha, which is highly elevated in HELUs and may be fundamental to their development. This study used DNA microarray technology and RNA from microdissected pure epithelial cells to learn more about changes in gene expression and molecular pathways associated with the development of HELUs from TDLUs Experiment Overall Design: Samples for the microarray studies were derived from 8 formalin-fixed paraffin-embedded tissue (FFPET) biopsies containing paired normal TDLUs and well-developed HELUs from non-cancerous adult female human breasts obtained within the past 3 years. Populations of nearly pure (>95%) epithelial cells were isolated from the TDLUs and HELUs in each biopsy (approximately 25,000 cells/sample) by laser capture microdissection (LCM)

2009-04-23 | E-GEOD-7377 | biostudies-arrayexpress

Histone H1 profiling in breast cancer samples

Project description:Epigenetic aberrations have been recognized as important contributors to cancer onset and development, and increasing evidence suggests that linker histone H1 variants may serve as biomarkers useful for patient stratification, as well as play an important role as drivers in cancer. Although traditionally histone H1 levels have been studied using antibody-based methods and RNA expression, these approaches suffer from limitations. Mass-spectrometry (MS)-based proteomics represents the ideal tool to accurately quantify relative changes in protein abundance within complex samples. We used a label-free quantification approach to simultaneously analyze all somatic histone H1 variants in breast cancer patient samples (different areas laser-microdissected from the same tumor sections, and triple negative samples with/without relapse 3 years after chemotherapy.

2021-03-16 | PXD020524 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data